While this target may be beneficial in some immunoreactive tumors by activating effector T cells and depleting regulatory T cells, they may be associated with an absence of response in less immunogenic tumor or even potentially lead to worse outcome by stimulating cancer cells expressing high level of GITR or GITRL. Here, TNFSF18 is linked to cancer.